+1 (704) 266-3234

Pancreatic Cancer Pipeline Review H1 2017

Published on: Jun 2017 | From USD $2500 | Published By: GMD | Number Of Pages: 2092

Pancreatic Cancer - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pancreatic Cancer - Pipeline Review, H1 2017, provides an overview of the Pancreatic Cancer (Oncology) pipeline landscape.

Pancreatic cancer is a disease in which malignant (cancer) cells are found in the tissues of the pancreas. This is also called exocrine cancer. Signs and symptoms include upper abdominal pain that may radiate to back, yellowing of skin and the whites of eyes (jaundice), loss of appetite, weight loss, depression and blood clots. Predisposing factors include age, gender, smoking, diabetes and family history. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pancreatic Cancer - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Pancreatic Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pancreatic Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Pancreatic Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 16, 120, 121, 2, 8, 273, 36 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 20, 9, 52 and 6 molecules, respectively.

Pancreatic Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Pancreatic Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Pancreatic Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Pancreatic Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Pancreatic Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Pancreatic Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Pancreatic Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Pancreatic Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents
Table of Contents 2
Introduction 13
Pancreatic Cancer - Overview 14
Pancreatic Cancer - Therapeutics Development 15
Pancreatic Cancer - Therapeutics Assessment 80
Pancreatic Cancer - Companies Involved in Therapeutics Development 117
Pancreatic Cancer - Drug Profiles 275
Pancreatic Cancer - Dormant Projects 1987
Pancreatic Cancer - Discontinued Products 2006
Pancreatic Cancer - Product Development Milestones 2011
Appendix 2027

List of Tables
Number of Products under Development for Pancreatic Cancer, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..7), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..8), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..9), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..10), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..11), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..12), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..13), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..14), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..15), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..16), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..17), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..18), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..19), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..20), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017 (Contd..3), H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Products under Development by Companies, H1 2017 (Contd..4), H1 2017
Products under Development by Companies, H1 2017 (Contd..5), H1 2017
Products under Development by Companies, H1 2017 (Contd..6), H1 2017
Products under Development by Companies, H1 2017 (Contd..7), H1 2017
Products under Development by Companies, H1 2017 (Contd..8), H1 2017
Products under Development by Companies, H1 2017 (Contd..9), H1 2017
Products under Development by Companies, H1 2017 (Contd..10), H1 2017
Products under Development by Companies, H1 2017 (Contd..11), H1 2017
Products under Development by Companies, H1 2017 (Contd..12), H1 2017
Products under Development by Companies, H1 2017 (Contd..13), H1 2017
Products under Development by Companies, H1 2017 (Contd..14), H1 2017
Products under Development by Companies, H1 2017 (Contd..15), H1 2017
Products under Development by Companies, H1 2017 (Contd..16), H1 2017
Products under Development by Companies, H1 2017 (Contd..17), H1 2017
Products under Development by Companies, H1 2017 (Contd..18), H1 2017
Products under Development by Companies, H1 2017 (Contd..19), H1 2017
Products under Development by Companies, H1 2017 (Contd..20), H1 2017
Products under Development by Companies, H1 2017 (Contd..21), H1 2017
Products under Development by Companies, H1 2017 (Contd..22), H1 2017
Products under Development by Companies, H1 2017 (Contd..23), H1 2017
Products under Development by Companies, H1 2017 (Contd..24), H1 2017
Products under Development by Companies, H1 2017 (Contd..25), H1 2017
Products under Development by Companies, H1 2017 (Contd..26), H1 2017
Products under Development by Companies, H1 2017 (Contd..27), H1 2017
Products under Development by Companies, H1 2017 (Contd..28), H1 2017
Products under Development by Companies, H1 2017 (Contd..29), H1 2017
Products under Development by Companies, H1 2017 (Contd..30), H1 2017
Products under Development by Companies, H1 2017 (Contd..31), H1 2017
Products under Development by Universities/Institutes, H1 2017
Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017
Products under Development by Universities/Institutes, H1 2017 (Contd..3), H1 2017
Products under Development by Universities/Institutes, H1 2017 (Contd..4), H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..5), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..6), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..7), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..8), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..9), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..10), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..11), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..12), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..13), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..14), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..15), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..6), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..7), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..8), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..9), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..10), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..11), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..12), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..13), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..14), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Pancreatic Cancer - Pipeline by 3-V Biosciences Inc, H1 2017
Pancreatic Cancer - Pipeline by 4P-Pharma SAS, H1 2017
Pancreatic Cancer - Pipeline by AB Science SA, H1 2017
Pancreatic Cancer - Pipeline by AbbVie Inc, H1 2017
Pancreatic Cancer - Pipeline by AbGenomics International Inc, H1 2017
Pancreatic Cancer - Pipeline by Ability Pharmaceuticals SL, H1 2017
Pancreatic Cancer - Pipeline by Actuate Therapeutics Inc, H1 2017
Pancreatic Cancer - Pipeline by Adamed Sp z oo, H1 2017
Pancreatic Cancer - Pipeline by Aduro BioTech Inc, H1 2017
Pancreatic Cancer - Pipeline by Advanced Cancer Therapeutics LLC, H1 2017
Pancreatic Cancer - Pipeline by Advantagene Inc, H1 2017
Pancreatic Cancer - Pipeline by Agenus Inc, H1 2017
Pancreatic Cancer - Pipeline by AGV Discovery SAS, H1 2017
Pancreatic Cancer - Pipeline by AIMM Therapeutics BV, H1 2017
Pancreatic Cancer - Pipeline by Alissa Pharma, H1 2017
Pancreatic Cancer - Pipeline by Allinky Biopharma, H1 2017
Pancreatic Cancer - Pipeline by Almac Discovery Ltd, H1 2017
Pancreatic Cancer - Pipeline by Altor BioScience Corp, H1 2017
Pancreatic Cancer - Pipeline by Ambrx Inc, H1 2017
Pancreatic Cancer - Pipeline by amcure GmbH, H1 2017
Pancreatic Cancer - Pipeline by American Gene Technologies International Inc, H1 2017
Pancreatic Cancer - Pipeline by Amgen Inc, H1 2017
Pancreatic Cancer - Pipeline by Anavex Life Sciences Corp, H1 2017
Pancreatic Cancer - Pipeline by Andarix Pharmaceuticals Inc, H1 2017
Pancreatic Cancer - Pipeline by ANP Technologies Inc, H1 2017
Pancreatic Cancer - Pipeline by AntiCancer Inc, H1 2017
Pancreatic Cancer - Pipeline by APEIRON Biologics AG, H1 2017
Pancreatic Cancer - Pipeline by Aphios Corp, H1 2017
Pancreatic Cancer - Pipeline by APIM Therapeutics AS, H1 2017
Pancreatic Cancer - Pipeline by Apogenix GmbH, H1 2017
Pancreatic Cancer - Pipeline by Aposense Ltd, H1 2017
Pancreatic Cancer - Pipeline by ARMO Biosciences Inc, H1 2017
Pancreatic Cancer - Pipeline by ArQule Inc, H1 2017
Pancreatic Cancer - Pipeline by Array BioPharma Inc, H1 2017
Pancreatic Cancer - Pipeline by Astellas Pharma Inc, H1 2017
Pancreatic Cancer - Pipeline by AstraZeneca Plc, H1 2017
Pancreatic Cancer - Pipeline by Aurigene Discovery Technologies Ltd, H1 2017
Pancreatic Cancer - Pipeline by Autotelic Inc, H1 2017
Pancreatic Cancer - Pipeline by AVEO Pharmaceuticals Inc, H1 2017
Pancreatic Cancer - Pipeline by Axcentua Pharmaceuticals AB, H1 2017
Pancreatic Cancer - Pipeline by Basilea Pharmaceutica Ltd, H1 2017
Pancreatic Cancer - Pipeline by Bavarian Nordic A/S, H1 2017
Pancreatic Cancer - Pipeline by Bayer AG, H1 2017
Pancreatic Cancer - Pipeline by BeiGene (Beijing) Co Ltd, H1 2017
Pancreatic Cancer - Pipeline by Bellicum Pharmaceuticals Inc, H1 2017
Pancreatic Cancer - Pipeline by Berg LLC, H1 2017
Pancreatic Cancer - Pipeline by BerGenBio ASA, H1 2017
Pancreatic Cancer - Pipeline by Beta Pharma Inc, H1 2017
Pancreatic Cancer - Pipeline by Bexion Pharmaceuticals LLC, H1 2017
Pancreatic Cancer - Pipeline by BeyondSpring Pharmaceuticals Inc, H1 2017
Pancreatic Cancer - Pipeline by Bio-Path Holdings Inc, H1 2017
Pancreatic Cancer - Pipeline by BioLineRx Ltd, H1 2017
Pancreatic Cancer - Pipeline by Biomar Microbial Technologies, H1 2017
Pancreatic Cancer - Pipeline by Biomunex Pharmaceuticals, H1 2017
Pancreatic Cancer - Pipeline by Bioncotech Therapeutics SL, H1 2017
Pancreatic Cancer - Pipeline by Bionomics Ltd, H1 2017
Pancreatic Cancer - Pipeline by BioNTech AG, H1 2017
Pancreatic Cancer - Pipeline by Biotest AG, H1 2017
Pancreatic Cancer - Pipeline by Biouniversa srl, H1 2017
Pancreatic Cancer - Pipeline by BLR Bio LLC, H1 2017
Pancreatic Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2017
Pancreatic Cancer - Pipeline by Boston Biomedical Inc, H1 2017
Pancreatic Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2017
Pancreatic Cancer - Pipeline by Cadila Pharmaceuticals Ltd, H1 2017
Pancreatic Cancer - Pipeline by Calithera Biosciences Inc, H1 2017
Pancreatic Cancer - Pipeline by Cancer Prevention Pharmaceuticals Inc, H1 2017
Pancreatic Cancer - Pipeline by Cantargia AB, H1 2017
Pancreatic Cancer - Pipeline by Cascadian Therapeutics Inc, H1 2017
Pancreatic Cancer - Pipeline by Cavion LLC, H1 2017
Pancreatic Cancer - Pipeline by CBT Pharmaceuticals Inc, H1 2017
Pancreatic Cancer - Pipeline by CCRP Therapeutics GmbH, H1 2017
Pancreatic Cancer - Pipeline by Celgene Corp, H1 2017
Pancreatic Cancer - Pipeline by Celleron Therapeutics Ltd, H1 2017
Pancreatic Cancer - Pipeline by Cellular Biomedicine Group Inc, H1 2017
Pancreatic Cancer - Pipeline by Celprogen Inc, H1 2017
Pancreatic Cancer - Pipeline by Celyad SA, H1 2017
Pancreatic Cancer - Pipeline by Centrose LLC, H1 2017
Pancreatic Cancer - Pipeline by Ceronco Biosciences, H1 2017
Pancreatic Cancer - Pipeline by ChemoCentryx Inc, H1 2017
Pancreatic Cancer - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2017
Pancreatic Cancer - Pipeline by Clovis Oncology Inc, H1 2017
Pancreatic Cancer - Pipeline by COARE Biotechnology Inc, H1 2017
Pancreatic Cancer - Pipeline by Codiak BioSciences Inc, H1 2017
Pancreatic Cancer - Pipeline by Concordia International Corp, H1 2017
Pancreatic Cancer - Pipeline by Confluence Life Sciences Inc, H1 2017
Pancreatic Cancer - Pipeline by Critical Outcome Technologies Inc, H1 2017
Pancreatic Cancer - Pipeline by CrystalGenomics Inc, H1 2017
Pancreatic Cancer - Pipeline by CTI BioPharma Corp, H1 2017
Pancreatic Cancer - Pipeline by Cyclacel Pharmaceuticals Inc, H1 2017
Pancreatic Cancer - Pipeline by CytomX Therapeutics Inc, H1 2017
Pancreatic Cancer - Pipeline by Cytori Therapeutics Inc, H1 2017
Pancreatic Cancer - Pipeline by CytRx Corp, H1 2017
Pancreatic Cancer - Pipeline by CyTuVax BV, H1 2017
Pancreatic Cancer - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2017
Pancreatic Cancer - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
Pancreatic Cancer - Pipeline by DEKK-TEC Inc, H1 2017
Pancreatic Cancer - Pipeline by Denceptor Therapeutics Ltd, H1 2017
Pancreatic Cancer - Pipeline by Diffusion Pharmaceuticals Inc, H1 2017
Pancreatic Cancer - Pipeline by Eisai Co Ltd, H1 2017
Pancreatic Cancer - Pipeline by Eleison Pharmaceuticals LLC, H1 2017
Pancreatic Cancer - Pipeline by Eli Lilly and Company, H1 2017
Pancreatic Cancer - Pipeline by Endor Nanotechnologies SL, H1 2017
Pancreatic Cancer - Pipeline by Ensemble Therapeutics Corp, H1 2017
Pancreatic Cancer - Pipeline by Ensol Biosciences Inc, H1 2017
Pancreatic Cancer - Pipeline by Erytech Pharma SA, H1 2017
Pancreatic Cancer - Pipeline by Esperance Pharmaceuticals Inc, H1 2017
Pancreatic Cancer - Pipeline by Etubics Corp, H1 2017
Pancreatic Cancer - Pipeline by Exelixis Inc, H1 2017
Pancreatic Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
Pancreatic Cancer - Pipeline by Faron Pharmaceuticals Oy, H1 2017
Pancreatic Cancer - Pipeline by FibroGen Inc, H1 2017
Pancreatic Cancer - Pipeline by Formosa Laboratories Inc, H1 2017
Pancreatic Cancer - Pipeline by Forty Seven Inc, H1 2017
Pancreatic Cancer - Pipeline by Fountain Biopharma Inc, H1 2017
Pancreatic Cancer - Pipeline by Fujifilm Corp, H1 2017
Pancreatic Cancer - Pipeline by Fusion Antibodies Ltd, H1 2017
Pancreatic Cancer - Pipeline by Galena Biopharma Inc, H1 2017
Pancreatic Cancer - Pipeline by GamaMabs Pharma SA, H1 2017
Pancreatic Cancer - Pipeline by Geistlich Pharma AG, H1 2017
Pancreatic Cancer - Pipeline by Genelux Corp, H1 2017
Pancreatic Cancer - Pipeline by Genentech Inc, H1 2017
Pancreatic Cancer - Pipeline by Genisphere LLC, H1 2017
Pancreatic Cancer - Pipeline by Genmab A/S, H1 2017
Pancreatic Cancer - Pipeline by Gilead Sciences Inc, H1 2017
Pancreatic Cancer - Pipeline by GlaxoSmithKline Plc, H1 2017
Pancreatic Cancer - Pipeline by Globeimmune Inc, H1 2017
Pancreatic Cancer - Pipeline by GlycoMimetics Inc, H1 2017
Pancreatic Cancer - Pipeline by Glycotope GmbH, H1 2017
Pancreatic Cancer - Pipeline by Golden Biotechnology Corp, H1 2017
Pancreatic Cancer - Pipeline by GW Pharmaceuticals Plc, H1 2017
Pancreatic Cancer - Pipeline by Halozyme Therapeutics Inc, H1 2017
Pancreatic Cancer - Pipeline by Helix BioPharma Corp, H1 2017
Pancreatic Cancer - Pipeline by Horizon Pharma Plc, H1 2017
Pancreatic Cancer - Pipeline by Humorigin Biotechnology Corp, H1 2017
Pancreatic Cancer - Pipeline by iCeutica Inc, H1 2017
Pancreatic Cancer - Pipeline by Idera Pharmaceuticals Inc, H1 2017
Pancreatic Cancer - Pipeline by Igenica Biotherapeutics Inc, H1 2017
Pancreatic Cancer - Pipeline by Ignyta Inc, H1 2017
Pancreatic Cancer - Pipeline by Immodulon Therapeutics Ltd, H1 2017
Pancreatic Cancer - Pipeline by Immune Pharmaceuticals Inc, H1 2017
Pancreatic Cancer - Pipeline by Immune System Key Ltd, H1 2017
Pancreatic Cancer - Pipeline by Immune Therapeutics Inc, H1 2017
Pancreatic Cancer - Pipeline by Immunitor Inc, H1 2017
Pancreatic Cancer - Pipeline by Immunomedics Inc, H1 2017
Pancreatic Cancer - Pipeline by Immunotope Inc, H1 2017
Pancreatic Cancer - Pipeline by Immunovo BV, H1 2017
Pancreatic Cancer - Pipeline by Immupharma Plc, H1 2017
Pancreatic Cancer - Pipeline by Incyte Corp, H1 2017
Pancreatic Cancer - Pipeline by Inflection Biosciences Ltd, H1 2017
Pancreatic Cancer - Pipeline by Innopharmax Inc, H1 2017
Pancreatic Cancer - Pipeline by Innovation Pharmaceuticals Inc, H1 2017
Pancreatic Cancer - Pipeline by Inovio Pharmaceuticals Inc, H1 2017
Pancreatic Cancer - Pipeline by InteRNA Technologies BV, H1 2017
Pancreatic Cancer - Pipeline by Intezyne Technologies Inc, H1 2017
Pancreatic Cancer - Pipeline by Inventiva, H1 2017
Pancreatic Cancer - Pipeline by InvivoGen Therapeutics, H1 2017
Pancreatic Cancer - Pipeline by Io Therapeutics Inc, H1 2017
Pancreatic Cancer - Pipeline by Ipsen SA, H1 2017
Pancreatic Cancer - Pipeline by ISU ABXIS Co Ltd, H1 2017
Pancreatic Cancer - Pipeline by Jasco Pharmaceuticals LLC, H1 2017
Pancreatic Cancer - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017
Pancreatic Cancer - Pipeline by Johnson & Johnson, H1 2017
Pancreatic Cancer - Pipeline by Juno Therapeutics Inc, H1 2017
Pancreatic Cancer - Pipeline by Kalyra Pharmaceuticals Inc, H1 2017
Pancreatic Cancer - Pipeline by Kancera AB, H1 2017
Pancreatic Cancer - Pipeline by Karcinolys SAS, H1 2017
Pancreatic Cancer - Pipeline by Karyopharm Therapeutics Inc, H1 2017
Pancreatic Cancer - Pipeline by Keystone Nano Inc, H1 2017
Pancreatic Cancer - Pipeline by Komipharm International Co Ltd, H1 2017
Pancreatic Cancer - Pipeline by Kura Oncology Inc, H1 2017
Pancreatic Cancer - Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2017
Pancreatic Cancer - Pipeline by Lead Discovery Center GmbH, H1 2017
Pancreatic Cancer - Pipeline by Lidds AB, H1 2017
Pancreatic Cancer - Pipeline by Lion Biotechnologies Inc, H1 2017
Pancreatic Cancer - Pipeline by Lipopharma Therapeutics SL, H1 2017
Pancreatic Cancer - Pipeline by Lixte Biotechnology Holdings Inc, H1 2017
Pancreatic Cancer - Pipeline by Loxo Oncology Inc, H1 2017
Pancreatic Cancer - Pipeline by Lymphocyte Activation Technologies SA, H1 2017
Pancreatic Cancer - Pipeline by MabVax Therapeutics Holdings Inc, H1 2017
Pancreatic Cancer - Pipeline by MacroGenics Inc, H1 2017
Pancreatic Cancer - Pipeline by Mateon Therapeutics Inc, H1 2017
Pancreatic Cancer - Pipeline by MaxiVAX SA, H1 2017
Pancreatic Cancer - Pipeline by Meabco A/S, H1 2017
Pancreatic Cancer - Pipeline by Mebiopharm Co Ltd, H1 2017
Pancreatic Cancer - Pipeline by MediaPharma Srl, H1 2017
Pancreatic Cancer - Pipeline by Medicenna Therapeutics Corp, H1 2017
Pancreatic Cancer - Pipeline by MedImmune LLC, H1 2017
Pancreatic Cancer - Pipeline by Medivir AB, H1 2017
Pancreatic Cancer - Pipeline by Merck & Co Inc, H1 2017
Pancreatic Cancer - Pipeline by Merck KGaA, H1 2017
Pancreatic Cancer - Pipeline by Merrimack Pharmaceuticals Inc, H1 2017
Pancreatic Cancer - Pipeline by Merus NV, H1 2017
Pancreatic Cancer - Pipeline by Millennium Pharmaceuticals Inc, H1 2017
Pancreatic Cancer - Pipeline by Moleculin Biotech Inc, H1 2017
Pancreatic Cancer - Pipeline by MolMed SpA, H1 2017
Pancreatic Cancer - Pipeline by Monopar Therapeutics LLC, H1 2017
Pancreatic Cancer - Pipeline by Morphotek Inc, H1 2017
Pancreatic Cancer - Pipeline by Mount Tam Biotechnologies Inc, H1 2017
Pancreatic Cancer - Pipeline by NanoCarrier Co Ltd, H1 2017
Pancreatic Cancer - Pipeline by NantKwest Inc, H1 2017
Pancreatic Cancer - Pipeline by Nascent Biotech Inc, H1 2017
Pancreatic Cancer - Pipeline by Natco Pharma Ltd, H1 2017
Pancreatic Cancer - Pipeline by NatureWise Biotech & Medicals Corp, H1 2017
Pancreatic Cancer - Pipeline by NBE-Therapeutics AG, H1 2017
Pancreatic Cancer - Pipeline by Nerviano Medical Sciences Srl, H1 2017
Pancreatic Cancer - Pipeline by NewLink Genetics Corp, H1 2017
Pancreatic Cancer - Pipeline by NormOxys Inc, H1 2017
Pancreatic Cancer - Pipeline by Northwest Biotherapeutics Inc, H1 2017
Pancreatic Cancer - Pipeline by Novartis AG, H1 2017
Pancreatic Cancer - Pipeline by Novogen Ltd, H1 2017
Pancreatic Cancer - Pipeline by Novus Therapeutics Inc, H1 2017
Pancreatic Cancer - Pipeline by Noxxon Pharma AG, H1 2017
Pancreatic Cancer - Pipeline by NuCana BioMed Ltd, H1 2017
Pancreatic Cancer - Pipeline by OBI Pharma Inc, H1 2017
Pancreatic Cancer - Pipeline by Omeros Corp, H1 2017
Pancreatic Cancer - Pipeline by Oncodesign SA, H1 2017
Pancreatic Cancer - Pipeline by Oncolytics Biotech Inc, H1 2017
Pancreatic Cancer - Pipeline by Oncomatryx Biopharma SL, H1 2017
Pancreatic Cancer - Pipeline by OncoMed Pharmaceuticals Inc, H1 2017
Pancreatic Cancer - Pipeline by OncoTherapy Science Inc, H1 2017
Pancreatic Cancer - Pipeline by Oncovir Inc, H1 2017
Pancreatic Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H1 2017
Pancreatic Cancer - Pipeline by Onxeo SA, H1 2017
Pancreatic Cancer - Pipeline by Opsona Therapeutics Ltd, H1 2017
Pancreatic Cancer - Pipeline by Optimum Therapeutics LLC, H1 2017
Pancreatic Cancer - Pipeline by Orega Biotech SAS, H1 2017
Pancreatic Cancer - Pipeline by Oribase Pharma, H1 2017
Pancreatic Cancer - Pipeline by Oryx GmbH & Co KG, H1 2017
Pancreatic Cancer - Pipeline by Patrys Ltd, H1 2017
Pancreatic Cancer - Pipeline by Pfizer Inc, H1 2017
Pancreatic Cancer - Pipeline by Pharma Two B Ltd, H1 2017
Pancreatic Cancer - Pipeline by PharmAbcine Inc, H1 2017
Pancreatic Cancer - Pipeline by PharmaCyte Biotech Inc, H1 2017
Pancreatic Cancer - Pipeline by Pharmedartis GmbH, H1 2017
Pancreatic Cancer - Pipeline by Phoenix Biotechnology Inc, H1 2017
Pancreatic Cancer - Pipeline by Plexxikon Inc, H1 2017
Pancreatic Cancer - Pipeline by Polaris Pharmaceuticals Inc, H1 2017
Pancreatic Cancer - Pipeline by Precision Biologics Inc, H1 2017
Pancreatic Cancer - Pipeline by Prima BioMed Ltd, H1 2017
Pancreatic Cancer - Pipeline by Propanac Biopharma Inc, H1 2017
Pancreatic Cancer - Pipeline by Provectus Biopharmaceuticals Inc, H1 2017
Pancreatic Cancer - Pipeline by Puretech Health plc, H1 2017
Pancreatic Cancer - Pipeline by Quest PharmaTech Inc, H1 2017
Pancreatic Cancer - Pipeline by Quimatryx SL, H1 2017
Pancreatic Cancer - Pipeline by Quintessence Biosciences Inc, H1 2017
Pancreatic Cancer - Pipeline by Rafael Pharmaceuticals Inc, H1 2017
Pancreatic Cancer - Pipeline by RedHill Biopharma Ltd, H1 2017
Pancreatic Cancer - Pipeline by Redx Pharma Plc, H1 2017
Pancreatic Cancer - Pipeline by Rexahn Pharmaceuticals Inc, H1 2017
Pancreatic Cancer - Pipeline by Rhizen Pharmaceuticals SA, H1 2017
Pancreatic Cancer - Pipeline by Samumed LLC, H1 2017
Pancreatic Cancer - Pipeline by Samyang Holdings Corp, H1 2017
Pancreatic Cancer - Pipeline by Sanofi, H1 2017
Pancreatic Cancer - Pipeline by Sareum Holdings Plc, H1 2017
Pancreatic Cancer - Pipeline by SATT North SAS, H1 2017
Pancreatic Cancer - Pipeline by Selecta Biosciences Inc, H1 2017
Pancreatic Cancer - Pipeline by Sierra Oncology Inc, H1 2017
Pancreatic Cancer - Pipeline by SignPath Pharma Inc, H1 2017
Pancreatic Cancer - Pipeline by Sillajen Biotherapeutics, H1 2017
Pancreatic Cancer - Pipeline by Soricimed Biopharma Inc, H1 2017
Pancreatic Cancer - Pipeline by Sorrento Therapeutics Inc, H1 2017
Pancreatic Cancer - Pipeline by Spring Bank Pharmaceuticals Inc, H1 2017
Pancreatic Cancer - Pipeline by Stelic Institute & Co Inc, H1 2017
Pancreatic Cancer - Pipeline by Strongbridge Biopharma plc, H1 2017
Pancreatic Cancer - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017
Pancreatic Cancer - Pipeline by Sun BioPharma Inc, H1 2017
Pancreatic Cancer - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017
Pancreatic Cancer - Pipeline by Sunshine Biopharma Inc, H1 2017
Pancreatic Cancer - Pipeline by Swedish Orphan Biovitrum AB, H1 2017
Pancreatic Cancer - Pipeline by Symic Biomedical Inc, H1 2017
Pancreatic Cancer - Pipeline by Symphogen A/S, H1 2017
Pancreatic Cancer - Pipeline by SynCore Biotechnology Co Ltd, H1 2017
Pancreatic Cancer - Pipeline by Synergys Biotherapeutics Inc, H1 2017
Pancreatic Cancer - Pipeline by Synovo GmbH, H1 2017
Pancreatic Cancer - Pipeline by SyntheX Inc, H1 2017
Pancreatic Cancer - Pipeline by Taiho Pharmaceutical Co Ltd, H1 2017
Pancreatic Cancer - Pipeline by Taiwan Liposome Company Ltd, H1 2017
Pancreatic Cancer - Pipeline by Takara Bio Inc, H1 2017
Pancreatic Cancer - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
Pancreatic Cancer - Pipeline by Takis Srl, H1 2017
Pancreatic Cancer - Pipeline by Targovax ASA, H1 2017
Pancreatic Cancer - Pipeline by Tarveda Therapeutics Inc, H1 2017
Pancreatic Cancer - Pipeline by tella Inc, H1 2017
Pancreatic Cancer - Pipeline by Threshold Pharmaceuticals Inc, H1 2017
Pancreatic Cancer - Pipeline by Tiltan Pharma Ltd, H1 2017
Pancreatic Cancer - Pipeline by Tocagen Inc, H1 2017
Pancreatic Cancer - Pipeline by Tolero Pharmaceuticals Inc, H1 2017
Pancreatic Cancer - Pipeline by Transcriptogen Ltd, H1 2017
Pancreatic Cancer - Pipeline by Transgene SA, H1 2017
Pancreatic Cancer - Pipeline by TVAX Biomedical Inc, H1 2017
Pancreatic Cancer - Pipeline by Tyg Oncology Ltd, H1 2017
Pancreatic Cancer - Pipeline by Tyme Technologies Inc, H1 2017
Pancreatic Cancer - Pipeline by Tyrogenex Inc, H1 2017
Pancreatic Cancer - Pipeline by UbiVac LLC, H1 2017
Pancreatic Cancer - Pipeline by ValiRx Plc, H1 2017
Pancreatic Cancer - Pipeline by VasGene Therapeutics Inc, H1 2017
Pancreatic Cancer - Pipeline by Vault Pharma Inc, H1 2017
Pancreatic Cancer - Pipeline by Vaxeal Holding SA, H1 2017
Pancreatic Cancer - Pipeline by Vaximm AG, H1 2017
Pancreatic Cancer - Pipeline by Vaxon Biotech, H1 2017
Pancreatic Cancer - Pipeline by VCN Biosciences SL, H1 2017
Pancreatic Cancer - Pipeline by Vect-Horus SAS, H1 2017
Pancreatic Cancer - Pipeline by Verastem Inc, H1 2017
Pancreatic Cancer - Pipeline by VG Life Sciences Inc, H1 2017
Pancreatic Cancer - Pipeline by Vicus Therapeutics LLC, H1 2017
Pancreatic Cancer - Pipeline by ViiV Healthcare Ltd, H1 2017
Pancreatic Cancer - Pipeline by Viralytics Ltd, H1 2017
Pancreatic Cancer - Pipeline by Virobay Inc, H1 2017
Pancreatic Cancer - Pipeline by ViroStatics srl, H1 2017
Pancreatic Cancer - Pipeline by Wilex AG, H1 2017
Pancreatic Cancer - Pipeline by Zeria Pharmaceutical Co Ltd, H1 2017
Pancreatic Cancer - Dormant Projects, H1 2017
Pancreatic Cancer - Dormant Projects, H1 2017 (Contd..1), H1 2017
Pancreatic Cancer - Dormant Projects, H1 2017 (Contd..2), H1 2017
Pancreatic Cancer - Dormant Projects, H1 2017 (Contd..3), H1 2017
Pancreatic Cancer - Dormant Projects, H1 2017 (Contd..4), H1 2017
Pancreatic Cancer - Dormant Projects, H1 2017 (Contd..5), H1 2017
Pancreatic Cancer - Dormant Projects, H1 2017 (Contd..6), H1 2017
Pancreatic Cancer - Dormant Projects, H1 2017 (Contd..7), H1 2017
Pancreatic Cancer - Dormant Projects, H1 2017 (Contd..8), H1 2017
Pancreatic Cancer - Dormant Projects, H1 2017 (Contd..9), H1 2017
Pancreatic Cancer - Dormant Projects, H1 2017 (Contd..10), H1 2017
Pancreatic Cancer - Dormant Projects, H1 2017 (Contd..11), H1 2017
Pancreatic Cancer - Dormant Projects, H1 2017 (Contd..12), H1 2017
Pancreatic Cancer - Dormant Projects, H1 2017 (Contd..13), H1 2017
Pancreatic Cancer - Dormant Projects, H1 2017 (Contd..14), H1 2017
Pancreatic Cancer - Dormant Projects, H1 2017 (Contd..15), H1 2017
Pancreatic Cancer - Dormant Projects, H1 2017 (Contd..16), H1 2017
Pancreatic Cancer - Dormant Projects, H1 2017 (Contd..17), H1 2017
Pancreatic Cancer - Dormant Projects, H1 2017 (Contd..18), H1 2017
Pancreatic Cancer - Discontinued Products, H1 2017
Pancreatic Cancer - Discontinued Products, H1 2017 (Contd..1), H1 2017
Pancreatic Cancer - Discontinued Products, H1 2017 (Contd..2), H1 2017
Pancreatic Cancer - Discontinued Products, H1 2017 (Contd..3), H1 2017
Pancreatic Cancer - Discontinued Products, H1 2017 (Contd..4), H1 2017 List of Figures
Number of Products under Development for Pancreatic Cancer, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Top 10 Routes of Administration, H1 2017
Number of Products by Stage and Top 10 Routes of Administration, H1 2017
Number of Products by Top 10 Molecule Types, H1 2017
Number of Products by Stage and Top 10 Molecule Types, H1 2017

SECONDARY RESEARCH
Secondary Research Information is collected from a number of publicly available as well as paid databases. Public sources involve publications by different associations and governments, annual reports and statements of companies, white papers and research publications by recognized industry experts and renowned academia etc. Paid data sources include third party authentic industry databases.

PRIMARY RESEARCH
Once data collection is done through secondary research, primary interviews are conducted with different stakeholders across the value chain like manufacturers, distributors, ingredient/input suppliers, end customers and other key opinion leaders of the industry. Primary research is used both to validate the data points obtained from secondary research and to fill in the data gaps after secondary research.

MARKET ENGINEERING
The market engineering phase involves analyzing the data collected, market breakdown and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.

EXPERT VALIDATION
The market engineered data is verified and validated by a number of experts, both in-house and external.

REPORT WRITING/ PRESENTATION
After the data is curated by the mentioned highly sophisticated process, the analysts begin to write the report. Garnering insights from data and forecasts, insights are drawn to visualize the entire ecosystem in a single report.

Please Choose License Type

USD $2500
USD $5000
USD $7500
Offer

Why Us

  • Why Us In-depth database
    Our Report’s database covers almost all topics of all regions over the Globe..
  • Why Us Recognised publishing sources
    Tie ups with top publishers around the globe.
  • Why Us Customer Support
    Complete pre and post sales support.
  • Why Us Safe & Secure
    Complete secure payment process.